Arrowhead Pharmaceuticals Inc. (ARWR)’s financial ratios: A comprehensive overview

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) closed the day trading at $32.26 down -0.92% from the previous closing price of $32.56. In other words, the price has decreased by -$0.30 from its previous closing price. On the day, 1244681 shares were traded. ARWR stock price reached its highest trading level at $33.02 during the session, while it also had its lowest trading level at $31.47.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Ratios:

For a better understanding of ARWR, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.73 and its Current Ratio is at 3.73. In the meantime, Its Debt-to-Equity ratio is 2.45 whereas as Long-Term Debt/Eq ratio is at 2.42.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BofA Securities on December 04, 2023, initiated with a Buy rating and assigned the stock a target price of $29.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 31 when Anzalone Christopher Richard sold 57,499 shares for $32.35 per share. The transaction valued at 1,860,019 led to the insider holds 3,715,048 shares of the business.

Hamilton James C sold 7,940 shares of ARWR for $292,904 on Jan 12. The Chief Discovery/Trans Medicine now owns 210,851 shares after completing the transaction at $36.89 per share. On Jan 11, another insider, Vakiener Victoria, who serves as the Director of the company, sold 4,720 shares for $38.10 each. As a result, the insider received 179,813 and left with 32,001 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 4.00B and an Enterprise Value of 3.90B. For the stock, the TTM Price-to-Sale (P/S) ratio is 21.99 while its Price-to-Book (P/B) ratio in mrq is 21.62. Its current Enterprise Value per Revenue stands at 21.44 whereas that against EBITDA is -14.51.

Stock Price History:

Over the past 52 weeks, ARWR has reached a high of $42.48, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 30.97, while the 200-Day Moving Average is calculated to be 31.14.

Shares Statistics:

Over the past 3-months, ARWR traded about 0.78 shares per day on average, while over the past 10 days, ARWR traded about 1.3M shares per day. A total of 123.90M shares are outstanding, with a floating share count of 116.45M. Insiders hold about 6.01% of the company’s shares, while institutions hold 61.34% stake in the company. Shares short for ARWR as of Jan 31, 2024 were 7.72M with a Short Ratio of 4.85, compared to 7.47M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.23% and a Short% of Float of 7.32%.

Earnings Estimates

Current recommendations for the stock of the company come from 13 analysts. On average, analysts expect EPS of -$0.22 for the current quarter, with a high estimate of $3.27 and a low estimate of -$0.96, while EPS last year was $0.45. The consensus estimate for the next quarter is -$0.66, with high estimates of -$0.24 and low estimates of -$1.01.

Analysts are recommending an EPS of between -$1.26 and -$4.07 for the fiscal current year, implying an average EPS of -$2.76. EPS for the following year is -$2.67, with 13 analysts recommending between -$1.46 and -$3.98.

Revenue Estimates

A total of 14 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $302M, while the lowest revenue estimate was $53.55M, resulting in an average revenue estimate of $135.17M. In the same quarter a year ago, actual revenue was $240.74M, down -43.90% from the average estimate.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular